Company Research Report: Becton, Dickinson and Company (BD)

Company Overview

• Name: Becton, Dickinson and Company (BD)

• Mission: Advancing the world of health by improving medical discovery, diagnostics, and delivery of care.

• Founded: No information is available about the exact founding date or founder(s).

• Key People:

• Tom Polen, Chairman, CEO, and President

• Headquarters: Franklin Lakes, New Jersey, USA

• Number of Employees: More than 70,000 employees

• Revenue: No specific revenue figures are provided.

• Known For: Developing innovative technology, services, and solutions to advance clinical therapy for patients and clinical processes for healthcare providers.

Products

• Product Offerings:

• BD Alaris™ Infusion System: Utilized in operating rooms or intensive care units, integrates advanced monitoring with infusion platforms for comprehensive care solutions.

• BD® OMICS-One XT WTA Assay and Hamilton® Microlab™ NGS STAR: A robotics-compatible reagent kit and automated platform facilitating single-cell discovery studies.

• High-Level Description: BD provides technologies used across healthcare settings including smart medical devices, lab automation, and connected medication management.

• Key Features:

• Advanced AI-enabled clinical decision tools.

• Automation-ready reagents for large-scale genomic sequencing.

• Emphasis on analytics with machine learning and AI-based predictive and prescriptive algorithms.

Recent Developments

• Recent Developments:

• Acquisition: BD completed the acquisition of Edwards Lifesciences' Critical Care product group, now renamed BD Advanced Patient Monitoring. This addition enhances BD's portfolio with advanced AI-enabled clinical tools.

• New Products Launched: Introduction of high-throughput reagent kits in collaboration with Hamilton to standardize and automate single-cell research.

• Partnerships and Collaborations:

• Newly formed partnerships for cervical and breast cancer screening with the Ministry of Health in Kenya and public-private sectors in Colombia and the U.S.

• BD's participation in the CHARME collaboration and the White House's Climate Pledge.

Additional Information

• Sustainability and Corporate Responsibility:

• Surpassed targets for GHG emissions reduction, demonstrating a strong commitment to environmental sustainability.

• Active involvement in reducing healthcare industry's climate footprint and enhancing circularity in product design and operations.

• Innovation Investment: Over $1 billion invested in breakthrough technologies to unlock new scientific and healthcare delivery frontiers.

This report compiles available data regarding Becton, Dickinson and Company (BD), which continuously pushes the boundaries of medical technology to address global healthcare challenges. The company's emphasis on innovation, sustainability, and operational excellence defines its ongoing commitment to improving global health.